Evidence map›Paper›PMID 32078628›Full record

ArticlePloS one2020

The PAR2 signal peptide prevents premature receptor cleavage and activation.

Belinda Liu, Grace Lee, Jiejun Wu, Janise Deming, Chester Kuei, Anthony Harrington, Lien Wang, Jennifer Towne, Timothy Lovenberg, Changlu Liu and 1 more

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Belinda LiuJanssen Research & Development, LLC, San Diego, California, United States of America.
Grace LeeJanssen Research & Development, LLC, San Diego, California, United States of America.
Jiejun WuJanssen Research & Development, LLC, San Diego, California, United States of America.
Janise DemingJanssen Research & Development, LLC, San Diego, California, United States of America.
Chester KueiJanssen Research & Development, LLC, San Diego, California, United States of America.
Anthony HarringtonJanssen Research & Development, LLC, San Diego, California, United States of America.
Lien WangJanssen Research & Development, LLC, San Diego, California, United States of America.
Jennifer TowneJanssen Research & Development, LLC, San Diego, California, United States of America.
Timothy LovenbergJanssen Research & Development, LLC, San Diego, California, United States of America.
Changlu LiuJanssen Research & Development, LLC, San Diego, California, United States of America.ORCID 0000-0001-6878-9384
Siquan SunJanssen Research & Development, LLC, San Diego, California, United States of America.
Janssen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unlike closely related GPCRs, protease-activated receptors (PAR1, PAR2, PAR3, and PAR4) have a predicted signal peptide at their N-terminus, which is encoded by a separate exon, suggesting that the signal peptides of PARs may serve an important and unique function, specific for PARs. In this report, we show that the PAR2 signal peptide, when fused to the N-terminus of IgG-Fc, effectively induced IgG-Fc secretion into culture medium, thus behaving like a classical signal peptide. The presence of PAR2 signal peptide has a strong effect on PAR2 cell surface expression, as deletion of the signal peptide (PAR2ΔSP) led to dramatic reduction of the cell surface expression and decreased responses to trypsin or the synthetic peptide ligand (SLIGKV). However, further deletion of the tethered ligand region (SLIGKV) at the N-terminus rescued the cell surface receptor expression and the response to the synthetic peptide ligand, suggesting that the signal peptide of PAR2 may be involved in preventing PAR2 from intracellular protease activation before reaching the cell surface. Supporting this hypothesis, an Arg36Ala mutation on PAR2ΔSP, which disabled the trypsin activation site, increased the receptor cell surface expression and the response to ligand stimulation. Similar effects were observed when PAR2ΔSP expressing cells were treated with protease inhibitors. Our findings indicated that there is a role of the PAR2 signal peptide in preventing the premature activation of PAR2 from intracellular protease cleavage before reaching the cells surface. The same mechanism may also apply to PAR1, PAR3, and PAR4.

Indexed as

AnimalsChlorocebus aethiopsCOS CellsEndopeptidasesHEK293 CellsHumansMutation, MissenseProtease InhibitorsProtein Sorting SignalsReceptor, PAR-1Receptor, PAR-2Receptors, Cell SurfaceTrypsinEndopeptidasesProtease InhibitorsProtein Sorting SignalsReceptor, PAR-1Receptor, PAR-2Receptors, Cell SurfaceTrypsin

Identifiers

PMID32078628
PMCPMC7032737
OpenAlexW3007571404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.